• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by NeOnc Technologies Holdings Inc.

    8/14/25 5:00:52 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    NT 10-Q 1 neonctech_nt10q.htm NT 10-Q

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     
    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    SEC FILE NUMBER
    001-42567
    CUSIP NUMBER
    64051A101

     

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR  
     

     

    For Period Ended: June 30, 2025

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    ☐ Transition Report on Form N-SAR

     

    For the Transition Period Ended: __________________________

     

     

    Read attached instruction sheet before preparing form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     
     

     

     

     

     

    PART I

    REGISTRANT INFORMATION

     

    NeOnc Technologies Holdings, Inc.

    Full Name of Registrant

     
     
    Former Name if Applicable
     
    23975 Park Sorrento, Suite 205
    Address of Principal Executive Office (Street and Number)
     
    Calabasas, CA 91302
    City, State and Zip Code

     

    PART II
    RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒   (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
           
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
           
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III
    NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    NeOnc Technologies Holdings, Inc. (the “Company”) could not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) without unreasonable effort or expense because the Company requires additional time to complete the final review of its financial statements and other disclosures in the Form 10-Q regarding non-cash expense charges to be recorded with respect to previously granted restricted stock units. The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    2

     

     

    PART IV
    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      Amir Heshmatpour   818   570-6844
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s).  

     

    ☒ Yes ☐ No

           
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?   ☐ Yes ☒ No
           
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.    

     

     

    NeOnc Technologies Holdings, Inc.
    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 14, 2025 By: /s/ Amir Heshmatpour
      Name:  Amir Heshmatpour
      Title: President

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    3

     

    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:31:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

    CALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeO

    1/30/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Updated Clinical Results

    CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. Since the Company's prior announcement and 8K event on November 12, 2025, an additional patient has achieved both durable long-term survival and radiographic remission, further strengthening the clinical signal observed with intranasal NEO100

    12/15/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

    CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhances and amplifies NEO100's therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. Utilizing an AI-driven, 3D-bioprinted New Approach Methodol

    12/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Chiang Ming-Fu (Alan) claimed ownership of 2,190,049 shares (SEC Form 3)

    3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 6:13:12 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    SEC Filings

    View All

    SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

    EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/13/26 12:15:21 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.

    424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/12/26 4:51:40 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by NeOnc Technologies Holdings Inc.

    S-1 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/6/26 4:48:06 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

    CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter & Recent Corporate Highlights Middle East – NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42's IROS, and completing ADGM incorpora

    11/14/25 4:01:00 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

    CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company's lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. "Compl

    11/13/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

    CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company's Scientific Advisory Board (SAB) will present data updates from the Company's ongoing Phase 1/2a NEO100-1 clinical trial and

    11/7/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

    CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di

    11/4/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

    CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P

    10/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care